.jpg "MannKind Gets a Sell Rating from Maxim Group")
In a report released today, Jason McCarthy from Maxim Group maintained a Sell rating on MannKind (NASDAQ: MNKD). The company’s shares opened today at $1.90, close to its 52-week low of $1.09.
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 9.5% and a 44.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
MannKind has an analyst consensus of Moderate Buy, with a price target consensus of $2.
See today’s analyst top recommended stocks >>
Based on MannKind’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $30.39 million. In comparison, last year the company had a GAAP net loss of $16.32 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.
Read More on MNKD:
